



## Programme workshop 1: Monitoring

25-26 September 2017

Venue: Novotel Budapest Centrum, Rakoczi ut 43-45, 1088 Budapest

Registration desk open on Sunday 24 September 5-8pm in Zsolnay foyer

### September 25

Time	Research oriented (Zsolnay room II+III)	Policy oriented (Palace room)
8.00	Registration - Coffee and tea	
8.45-9.15	<p>1. Opening: Welcome, introducing EU-TOPIA (where we are now), goals of workshop 1, relation with IARC, harms vs benefits definition</p> <p><b>Harry de Koning</b></p>	
9.15-9.30	<p>2. Speech by <b>Dr. Miklós Szócska</b></p> <p>Former Minister of State for Health of Hungary, the Director of The Health Services Management Training Centre of the Semmelweis University</p>	
9.30-10.15	<p>3. Using indicators to predict the harms and benefits of screening: 3 country examples</p> <p><i>In this session it will be shown how to use the policy cycle and how policies can be changed by the use of indicators.</i></p> <p>Chair: <b>Harry de Koning</b></p> <ol style="list-style-type: none"> <li>1. Slovenia: colorectal cancer screening (10 min) – <b>Dominika Novak Mlakar</b></li> <li>2. Italy: monitoring of treatment of screen-detected and clinically diagnosed breast cancers (10 min) – <b>Mariano Tomatis</b></li> <li>3. Hungary: cervical cancer screening uptake (10 min) – <b>Attila Kovács</b></li> <li>4. Plenary discussion (15 minutes)</li> </ol>	
10.15-10.45	Coffee break	
10.45-12.00	<p>4a. A Delphi study: What are the most important indicators for screening effect, and why?</p> <p><i>In this session we will present the results of the survey and will try to reach consensus about screening indicators by voting. Disagreements will be discussed with a panel of experts.</i></p> <p>Chair: <b>Zoltán Vokó</b></p>	<p>4b. What defines a screening programme? A discrete choice experiment by voting about what elements make a successful screening programme</p> <p><b>Martin McKee</b> <b>Jennifer Priaulx</b></p> <ol style="list-style-type: none"> <li>1. Present background to discrete choice experiment</li> <li>2. Present results from pre-workshop discrete choice experiment</li> <li>3. Moderated group discussion of results</li> </ol>

12.00-13.00	<p>5a. Follow up of session 4a:</p> <ol style="list-style-type: none"> <li>1. Demonstration of important indicators and addressing variability of observed indicators – <b>Nereo Segnan</b></li> </ol> <p><i>In this session we will give example of important screening indicators, based on results of the IARC project ‘cancer screening in the EU’</i></p> <ol style="list-style-type: none"> <li>2. Demonstration of the monitoring tool – <b>Carlo Senore</b></li> </ol> <p><i>In this session we will show the tool that will be used to collect data in EU-TOPIA and will explain differences compared to the tool used in IARC project ‘cancer screening in the EU’</i></p>	<p>5b. How can policy changes make a differences in health? 4 country examples</p> <p><i>Chair: <b>Vanessa Kääb-Sanyal</b></i></p> <ol style="list-style-type: none"> <li>1. <i>Germany: law on data linkage (15 min) – <b>Vanessa Kääb-Sanyal</b></i></li> <li>2. <i>Legal access to screening data - lessons learned from the Norwegian challenges (15 min) – <b>Harald Weedon- Fekjær (Advisory Board)</b></i></li> <li>3. <i>Challenges to receive follow-up data in the Netherlands as a result of the General Data Protection Regulation (GDPR) (15 min) – <b>Linda Grievink</b></i></li> <li>4. <i>Organized cancer screening program in the Republic of Serbia: <b>Verica Jovanovic</b> (15 min)</i></li> </ol>
13.00-14.00	Lunch break	
14.00-15.30	<p>6a. ‘Is the perfect the enemy of the good?’</p> <p><i>In this session country examples will show how we can measure indicators</i></p> <p><i>Chair: <b>Iris Lansdorp-Vogelaar</b></i></p> <ol style="list-style-type: none"> <li>1. <i>Introduction (10 min)</i></li> <li>2. <i>Finland (20 min) - <b>Tytti Sarkeala</b></i></li> <li>3. <i>France (20 min) – <b>Françoise Hamers</b></i></li> <li>4. <i>Hungary (20 min) – <b>Marcell Csanádi</b></i></li> <li>5. <i>Plenary discussion (20 min)</i></li> </ol>	<p>6b. Discussion of the expectations of EU-TOPIA, what evidence (outcome measures) is needed to change a screening programme? What can be expected from the barrier analysis in EU-TOPIA?</p> <p><i>In this session the results of the survey will be discussed and we will vote on propositions for most important policy questions in plenary group. Also, the barrier assessment will be introduced.</i></p> <p><b>Martin McKee</b> <b>Jennifer Priaulx</b></p> <ol style="list-style-type: none"> <li>1. <i>Barrier assessment: Results of the survey presented and discussed (30 min)</i></li> <li>2. <i>Individual small group discussions about most important policy questions (30 min)</i></li> <li>3. <i>Vote on most important policy questions in plenary group (30 min)</i></li> </ol>

15.30-16.00	Coffee break
16.00-17.30	<p>7. Summary of day one</p> <ol style="list-style-type: none"> <li>Summary of both tracks (30 min) ('research oriented' and 'policy oriented') – <b>Harry de Koning</b></li> <li>Show the first results of the exemplary countries (20 min) - <b>Inge de Kok</b></li> <li>Q&amp;A with the EU-TOPIA working group (20 min)</li> <li>Perspective on Workshop 2: Evaluation, including a demonstration of the evaluation tool (20 min) - <b>Nicolien van Ravesteijn</b></li> </ol>
19.00-22.00	Dinner

## September 26

Time	(Zsolnay room II+III)
9.00-10.00	<p>1. Results of the CANCON project, presentation of EU guidelines. Discussion: in what respect are EU benchmarks used?</p> <p><b>Ahti Anttila</b> <b>Sirpa Heinävaara</b></p>
10.00-11.30	<p>2. Presentation of the results of the IARC project 'cancer screening in the EU': what are the most important pitfalls by collection of data?</p> <p><i>In this session we will present difficulties (i.e. problems in definitions) on different levels of data collection (i.e. data availability, definitions, organisation of the screening programme).</i></p> <ol style="list-style-type: none"> <li>Presentation of general results of the EU screening report (20 min) – <b>Carlo Senore</b></li> <li>Individual data to overcome pitfalls of aggregated data collection (15 min) – <b>Nereo Segnan</b></li> <li>Plenary discussion (10 min)</li> <li>Working groups by cancer site, discussing in detail the presented issues, using also the results of the report (45 min)</li> </ol>
11.30-12.30	Lunch break
12.30-14.00	<p>3. Which indicators are most important for the evaluation (Workshop 2)?</p> <p><i>In this session we will (in small groups by region) discuss which data sources can be used and all participants will develop a data collection plan.</i></p> <p><i>Chair: Iris Lansdorp-Vogelaar</i></p>
14.00-14.30	<p>4. Wrap up</p> <p><b>Harry de Koning</b></p>